Core Viewpoint - Shenzhen Mindray Bio-Medical Electronics Co., Ltd. is conducting a significant investor survey involving 183 institutions and 343 participants, indicating strong interest in the company's internationalization strategy and upcoming H-share IPO [1][2]. Group 1: Investor Survey Details - The investor survey includes various activities such as targeted research, roadshows, site visits, and conference calls, scheduled from September 1 to October 14, 2025 [1]. - Notable participating institutions include 3W Fund Management Limited and Principal Financial Group, Inc., showcasing the involvement of prominent investment firms [1]. Group 2: Internationalization Strategy - The upcoming overseas listing is a key initiative in the company's internationalization strategy, aimed at enhancing global influence and facilitating business and capital globalization [2]. - The company anticipates that the current market environment is favorable for international capital operations, with expectations of positive revenue growth in Q3 2025 [2]. Group 3: IPO Details and Fund Utilization - The H-share IPO is progressing well, with plans to issue no more than 10% of the total share capital post-issue, along with a 15% overallotment option [2]. - Proceeds from the IPO will be used to advance internationalization, increase R&D investment, and supplement operational funds, with potential future overseas acquisitions [2]. Group 4: Business Impact and Strategies - A successful listing in Hong Kong is expected to enhance international visibility, broaden financing channels, and accelerate overseas business expansion [2]. - The company has proactively addressed U.S. tariff challenges since 2018, ensuring continued market growth and profitability in the U.S. [2]. Group 5: Shareholder Interests and AI Product Highlights - The company is committed to protecting minority shareholder interests through performance growth, stable dividends, and transparent information disclosure, with a plan for cash dividends to be at least 65% of distributable profits annually from 2025 to 2027 [2]. - The launch of the AI-based perioperative medical model and new IVD products is expected to enhance operational efficiency and increase installed capacity [2].

Group 1: Purpose of Overseas Listing - The overseas listing aims to strengthen international influence and align with the company's global development strategy, as it ranks among the top 30 global medical device companies with nearly half of its revenue from international business [2][3] - The listing will enhance the company's ability to connect with overseas market resources, providing strong capital support for competition with international giants [3][4] - It will facilitate the design and implementation of global employee incentive plans, attracting top talent for sustainable development [3][4] Group 2: Timing and Market Conditions - The current period is deemed the best strategic window for overseas listing due to significant changes in the global medical industry, driven by factors like aging populations and technological advancements [4][5] - The stable capital market environment in Hong Kong is favorable for high-quality assets, making it an opportune time for international capital operations [5][6] Group 3: Financial Projections and Growth - The company expects a positive year-on-year growth in overall revenue by Q3 2025, with international business growth accelerating due to ongoing localization efforts [5][6] - Domestic market recovery is anticipated, although the revenue recognition cycle has lengthened, indicating a gradual improvement starting in Q3 [5][6] Group 4: Use of Funds from IPO - The funds raised from the IPO will be allocated to advancing international strategies, enhancing R&D investments, and supporting operational needs [8][9] - The company emphasizes a focus on self-research and development, with acquisitions serving as a supplementary strategy to enhance core competitiveness [9][10] Group 5: Shareholder Value and Communication - The company is committed to protecting minority shareholders' interests through performance growth, stable dividends, and transparent information disclosure [11][12] - A profit distribution policy has been established, ensuring at least 65% of distributable profits are allocated to dividends, with a total dividend payout of 35.7 billion CNY since its IPO [12][13] Group 6: Innovations in Medical Technology - The launch of new AI models and high-speed biochemical analysis systems aims to enhance clinical decision-making and improve operational efficiency [13][14][15] - The new systems are designed to address common challenges in testing, significantly improving speed and accuracy, thereby supporting market share growth [15][16]

登录新浪财经APP 搜索【信披】查看更多考评等级 迈瑞医疗（证券代码：300760）于2025年10月14日发布《关于控股股东部分股份质押的公告》。公告显 示，公司近日接到控股股东Magnifice(HK)Limited通知，其对所持公司部分股份办理了质押业务。 股份质押基本情况 | 股东名称 | 是否为控股股东或第一大股东及其一致行动人 | 本次质押数量(股) | 占其所持股份比例 | 占公 司总股本比例 | 是否为限售股 | 是否为补充质押 | 质押起始日 | 质押到期日 | 质权人 | 质押用途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | Magnifice (HK) | 是 | 4,400,000 | 1.48% | 0.36% | 否 | 否 | 2025年10月13日 | 至办理解除质押登记手续之日止 |兴业银行股份有限公司香港分行 | 其他 | 此外，上述质押的股份不存在冻结、拍卖或设定信托的情况，目前也不存在平仓风险。若后续出现平仓 风险，上述股东将积极采取措施应对，公司也将按规定及时履行信息披露义务。公告 ...

Core Viewpoint - Mindray Medical (300760) announced the appointment of Gu Minkang as an independent director of the company's eighth board of directors [1] Company Summary - The board of directors of Mindray Medical has approved the nomination of Gu Minkang as an independent director [1]

Group 1: Company Announcements - Mindray Medical plans to issue H-shares and list on the Hong Kong Stock Exchange, pending shareholder and regulatory approvals [1] - Shenghe Resources expects a net profit increase of 696.82% to 782.96% for the first three quarters of 2025, driven by favorable market demand and price increases for rare earth products [2] - Shandong Gold anticipates a net profit increase of 83.9% to 98.5% for the first three quarters of 2025, attributed to improved operational efficiency and rising gold prices [3] - Newray Materials reports significant stock price volatility, indicating potential market overreaction, although no fundamental changes have occurred [4] - Longbai Group's subsidiary has filed a lawsuit for technology infringement, with the amount involved totaling 1.311 billion yuan [5] - Chengdu Huami has launched a new RF transceiver chip, marking a significant breakthrough in its product line, although it is still in the early stages of market introduction [6] - Zhuhai Port has received approval from the CSRC to issue up to 1 billion yuan in technology innovation bonds [7] - Shengton Mining plans to acquire 100% of Canadian Loncor for approximately 1.9 billion USD, with core assets including a significant gold mining project in the Democratic Republic of Congo [8][9] Group 2: Financial Performance - Xiaogoods City reports a 100.52% increase in net profit for Q3 2025, with total revenue of 5.348 billion yuan, up 39.02% year-on-year [10] - Xianda Co. expects a net profit increase of 2807.87% to 3211.74% for the first three quarters of 2025, driven by rising prices of its main product [11] - Xianggang Technology anticipates a net profit increase of 182% to 200% for the first three quarters of 2025, supported by market expansion efforts [12] - Tongda Co. expects a net profit increase of 50.01% to 111.12% for the first three quarters of 2025, due to increased orders and delivery volumes [13] - Rockchip expects a net profit increase of 116% to 127% for the first three quarters of 2025, driven by growth in the AIoT market [14] - Jiantou Energy anticipates a net profit increase of 231.75% for the first three quarters of 2025, attributed to lower costs in its thermal power business [15] - Chongqing Steel expects a loss of 210 million to 230 million yuan for the first three quarters of 2025, an improvement from a loss of 1.35 billion yuan in the same period last year [16] - Yuanda Intelligent expects a net profit of 33.84 million to 50.74 million yuan for the first three quarters of 2025, recovering from a loss in the previous year [17] - China Metallurgical Group reports a 14.7% decline in new contracts signed in the first nine months of 2025, totaling 760.67 billion yuan, while overseas contracts increased by 10.1% [18]

Core Viewpoint - Mindray Medical (300760.SZ) plans to issue overseas listed foreign shares (H-shares) and list on the main board of the Hong Kong Stock Exchange to enhance its capital strength and support its internationalization strategy [1] Group 1 - The company aims to deepen its international strategy and create an international capital operation platform [1] - The issuance will consider the interests of existing shareholders and the conditions of domestic and foreign capital markets [1] - The company will complete the issuance and listing within 24 months after the shareholders' meeting resolution or within an extended period if agreed [1]

(本文来自第一财经) 迈瑞医疗公告，公司于2025年10月14日召开第八届董事会第十四次会议，审议通过了发行H股股票并在 香港联交所主板挂牌上市的相关议案。公司拟发行境外上市外资股（H股）股票，并考虑在股东会决议 有效期内选择适当的时机和发行窗口完成本次发行并上市。本次发行并上市尚需提交公司股东会审议， 并取得相关政府部门、监管机构、证券交易所的批准、核准或备案。目前其他具体细节尚未最终确定。 ...

格隆汇10月14日丨迈瑞医疗(300760.SZ)公布，为满足公司业务发展需要，深入推进国际化战略，打造 国际化资本运作平台，进一步提升公司资本实力，经公司充分研究论证，公司拟发行境外上市外资股 （H股）股票并在香港联合交易所有限公司（简称"香港联交所"）主板挂牌上市。公司将充分考虑现有 股东的利益和境内外资本市场的情况，在股东会决议有效期内（即经公司股东会审议通过之日起24个月 或同意延长的其他期限）选择适当的时机和发行窗口完成本次发行并上市。 ...

根据《中华人民共和国公司法》《中华人民共和国证券法》《深圳证券交易所上市公司 自律监管指引第2号—创业板上市公司规范运作》《境内企业境外发行证券和上市管理试行 办法》《香港联合交易所有限公司证券上市规则》等有关规定，公司本次发行并上市尚需提 交公司股东会审议，并需要取得中国证券监督管理委员会、香港证券及期货事务监察委员 会和香港联交所等相关政府部门、监管机构、证券交易所的批准、核准或备案。 截至目前，除本次董事会审议通过的相关议案外，其他关于本次发行并上市的具体细 节尚未最终确定。 关于筹划发行H股股票并上市相关事项的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 深圳迈瑞生物医疗电子股份有限公司（以下简称"公司"）于2025年10月14日召开第八 届董事会第十四次会议，审议通过了《关于公司发行H股股票并在香港联合交易所有限公司 上市的议案》《关于公司发行H股股票并在香港联合交易所有限公司上市方案的议案》等相 关议案。现将相关事项公告如下： 为满足公司业务发展需要，深入推进国际化战略，打造国际化资本运作平台，进一步 提升公司资本实力，经公司充分研究 ...

一、修订《公司章程》及其附件情况 鉴于公司拟发行境外上市外资股（H股）股票并在香港联合交易所有限公司（以下简称 "香港联交所"）主板挂牌上市（以下简称"本次发行并上市"），为进一步完善公司治理结 构，符合境内外有关法律法规的规定以及相关监管要求，根据《香港联合交易所有限公司 证券上市规则》等规定，对《深圳迈瑞生物医疗电子股份有限公司章程》及其附件条款进 行相应修改，形成本次发行并上市后适用的《深圳迈瑞生物医疗电子股份有限公司章程（草 案）》及其附件《深圳迈瑞生物医疗电子股份有限公司股东会议事规则（草案）》《深圳迈瑞 生物医疗电子股份有限公司董事会议事规则（草案）》。《深圳迈瑞生物医疗电子股份有限公 司章程（草案）》及其附件经公司股东会审议批准后，自公司本次发行的H股股票在香港联 交所挂牌上市之日起生效。 1.《深圳迈瑞生物医疗电子股份有限公司章程（草案）》的条款具体修改对照如下： | 修改前的条款 | 修改后的条款 | | --- | --- | | 深圳迈瑞生物医疗电子股份有限公司 | 深圳迈瑞生物医疗电子股份有限公司 | | 章程 | 章程 | | 2025年4月 | （草案） | | | （H股发行并上 ...